WILLIAM SELLERS
Broker in Boston, MA
License number
Massachusetts 70699
Issued Date
Aug 1, 1985
Expiration Date
Jul 16, 1987
Type
Salesperson
Address
Address
Boston, MA 02115
Professional information
William Sellers
Location:
Greater Boston Area
Industry:
Market Research
Skills:
FMCG, Vertical Marketing, Customer Insight, Competitive Analysis, SaaS, Analytics, Segmentation
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
8105769, Jan 31, 2012
Filed:
Aug 20, 2007
Appl. No.:
11/894135
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
8465916, Jun 18, 2013
Filed:
Aug 20, 2007
Appl. No.:
11/894160
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Prostate Cancer Diagnosis And Outcome Prediction By Expression Analysis
US Patent:
2006000, Jan 12, 2006
Filed:
Sep 6, 2005
Appl. No.:
11/221302
Inventors:
Todd Golub - Newton MA, US
Phillip Febbo - Jamaica Plain MA, US
Kenneth Ross - Boston MA, US
William Sellers - Chestnut Hill MA, US
Phillip Febbo - Jamaica Plain MA, US
Kenneth Ross - Boston MA, US
William Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Prostate Cancer Diagnosis And Outcome Prediction By Expression Analysis
US Patent:
6949342, Sep 27, 2005
Filed:
Dec 19, 2002
Appl. No.:
10/325457
Inventors:
Todd R. Golub - Newton MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q001/68, G01N033/53
US Classification:
435 6, 435 71
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
7294468, Nov 13, 2007
Filed:
Dec 5, 2005
Appl. No.:
11/294621
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6, 424 91, 435 912
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Prostate Cancer Diagnosis And Outcome Prediction By Expression Analysis
US Patent:
7501248, Mar 10, 2009
Filed:
Sep 26, 2005
Appl. No.:
11/236702
Inventors:
Todd R. Golub - Newton MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Phillip G. Febbo - Jamaica Plain MA, US
Kenneth N. Ross - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments
US Patent:
7964349, Jun 21, 2011
Filed:
Aug 20, 2007
Appl. No.:
11/894159
Inventors:
Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US
Assignee:
The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Tuberous Sclerosis Treatment
US Patent:
2010030, Dec 2, 2010
Filed:
Jan 31, 2007
Appl. No.:
12/162521
Inventors:
William Berg - New City NY, US
John Benedetto - Morristown NJ, US
Ingrid Elmroth - Riehen, CH
Heidi Lane - Biel-Benken, CH
David Lebwohl - Madison NJ, US
William Sellers - Chestnut Hill MA, US
Michael Stumm - Riehen, CH
John Benedetto - Morristown NJ, US
Ingrid Elmroth - Riehen, CH
Heidi Lane - Biel-Benken, CH
David Lebwohl - Madison NJ, US
William Sellers - Chestnut Hill MA, US
Michael Stumm - Riehen, CH
International Classification:
A61K 31/4353, A61P 25/00
US Classification:
514291
Abstract:
Rapamycin derivatives for use in the treatment of neurocutaneous disorders.